文献速递泌尿生殖技术与安全PETCTMR

不同配体PSMA PET在前列腺癌根治性治疗后生化复发患者中的检出率:前瞻性研究的系统综述与Meta分析

Detection Rate of PSMA PET Using Different Ligands in Men with Biochemical Recurrent Prostate Cancer Following Radical Treatment: A Systematic Review and Meta-analysis of Prospective Studies.
PubMed 文献 · Acad Radiol · 2023-09-27

该系统综述与Meta分析纳入32篇前瞻性研究共6800例根治性治疗后生化复发的前列腺癌患者,PSMA PET总体检出率为0.67(95%CI 0.63–0.71),组织学证实的淋巴结阳性预测值为0.96(95%CI 0.93–0.99)。PSA 0–0.5、0.5–1.0、1.0–2.0和>2.0 ng/ml亚组的检出率分别为0.44、0.63、0.82和0.94;PSA 1–2 ng/ml时18F PSMA检出率优于68Ga PSMA(0.91,95%CI 0.81–0.99 vs. 0.79,95%CI 0.73–0.85)。作者指出该结论存在较重偏倚,需进一步研究改进方法学以降低偏倚风险。

要点

  • PSMA PET对根治性治疗后生化复发前列腺癌的总体检出率为0.67(95%CI 0.63–0.71)。
  • PSA 0–0.5、0.5–1.0、1.0–2.0、>2.0 ng/ml亚组检出率分别为0.44、0.63、0.82、0.94,PSA>1 ng/ml后检出率明显提升。
  • PSA 1–2 ng/ml时18F PSMA检出率0.91(95%CI 0.81–0.99)优于68Ga PSMA的0.79(95%CI 0.73–0.85)。

核心结论

  • PSMA PET对根治性治疗后生化复发的前列腺癌转移复发有较好的检出率,血清PSA>1 ng/ml后检出率显著提升;PSA 1–2 ng/ml时18F-PSMA检出率优于68Ga PSMA,但该结论存在较重偏倚,需进一步研究改进方法学以降低偏倚风险。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、MEDLINE、Embase和Scopus自建库至2023年3月1日,纳入随机对照试验及前瞻性研究,共32篇文章、6800例患者,采用随机效应模型计算合并检出率及95%CI,并评估研究间异质性和偏倚风险。

诊断标准与关键数值

  • PSMA PET(CT和MR)总体检出率为0.67(95%CI 0.63–0.71);组织学证实淋巴结的阳性预测值来自13项前瞻性研究1496例患者,为0.96(95%CI 0.93–0.99);按PSA 0–0.5、0.5–1.0、1.0–2.0、>2.0 ng/ml分组检出率分别为0.44、0.63、0.82、0.94;PSA 1–2 ng/ml时18F PSMA检出率0.91(95%CI 0.81–0.99),68Ga PSMA为0.79(95%CI 0.73–0.85)。

临床应用与阅片要点

  • 作者认为PSMA PET对根治性治疗后生化复发前列腺癌转移复发检出率良好,PSA>1 ng/ml后检出率显著提升,PSA 1–2 ng/ml时18F-PSMA检出率优于68Ga PSMA;作者同时指出该结论存在较重偏倚,需进一步研究改进方法学以降低偏倚风险。

局限性

  • 作者指出该结论存在较重偏倚。
  • 作者指出需进一步研究以改进方法学、降低偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging in prostate cancer, little is known about the quality of evidence, particularly focusing on prospective studies. Most systematic reviews are based on retrospective reports.

RATIONALE AND OBJECTIVES: To conduct systematic review and meta-analysis of prospective studies reporting the diagnostic detection rate of PSMA PET (computed tomography (CT) and MR) for the detection of biochemically recurrent metastatic prostate cancer.

MATERIALS AND METHODS: We systematically searched PubMed, MEDLINE, Embase, and Scopus, from database until March 1, 2023 for randomized controlled trials and prospective studies using PSMA PET imaging in prostate cancer. The primary endpoint was to assess diagnostic detection rate of PSMA PET imaging in the detection of recurrent prostate cancer in men with biochemical relapse following radical treatment. We calculated the pooled overall diagnostic detection rate with 95% CI using a random-effects model and assessed the heterogeneity between the studies including risk of biases estimation.

RESULTS: A total of 6800 patients from 32 articles were included in this study. The overall detection rate of PSMA PET for prostate cancer was 0.67 (95% CI, 0.63, 0.71). For histologically confirmed lymph nodes, the PPV from 13 prospective studies containing 1496 patients was 0.96 (95% CI, 0.93, 0.99). We performed a subgroup analysis of PSMA PET detection rates according to categorically grouped Prostate Specific Antigen (PSA) values of 0-0.5, 0.5-1.0, 1.0-2.0, and >2.0 ng/ml and obtained detection rates of 0.44, 0.63, 0.82, and 0.94, respectively. The detection rate of 18F PSMA was better in men with a PSA between 1 ng/ml and 2 ng/ml in comparison to 68Ga PSMA (0.91 with 95% CI 0.81-0.99 vs. 0.79 with 95% CI 0.73, 0.85).

CONCLUSION: PSMA PET imaging provides a good detection rate for the metastatic recurrence of prostate cancer in men with biochemical relapse following radical treatment. The detection rate improves significantly above a serum PSA value of 1 ng/ml. The diagnostic detection rate of 18F-PSMA is best at PSA values between 1 and 2 ng/ml, in comparison to 68Ga PSMA. This conclusion is heavily biased, further research needs to focus on better methodology to minimize the risk of biases.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Wu Q, Bates A, Guntur P, et al. Detection Rate of PSMA PET Using Different Ligands in Men with Biochemical Recurrent Prostate Cancer Following Radical Treatment: A Systematic Review and Meta-analysis of Prospective Studies. Acad Radiol. 2023. PMID: 37770370. doi:10.1016/j.acra.2023.08.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。